Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Acrivon Therapeutics (Nasdaq: ACRV) will present at the TD Cowen 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 at 1:50 p.m. ET.
Peter Blume-Jensen, M.D., Ph.D., president and CEO, will appear in a fireside chat. A live and archived webcast will be available via the company's Events & Presentations investor webpage.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | CLIA lab certification | Positive | -0.6% | Completion and CLIA certification of internal clinical laboratory in Watertown. |
| Jan 23 | Conference presentation | Positive | +1.0% | Late-breaking oral presentation of interim ACR-368 Phase 2b data at ESGO. |
| Jan 08 | Clinical data update | Positive | -34.6% | Positive ACR-368 Phase 2b data, ACR-2316 initial data, and AP3 pipeline update. |
| Jan 06 | Upcoming data webcast | Positive | +31.4% | Announcement of planned webcast for ACR-368 and ACR-2316 clinical updates. |
| Dec 17 | Webcast preview | Positive | -4.5% | Advance notice of January 2026 clinical and pipeline update webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ACRV news has often seen negative or muted price reactions even on seemingly positive clinical or strategic updates, with more divergences than alignments.
Over the last few months, Acrivon reported several clinically and strategically positive updates, including strong ACR-368 Phase 2b efficacy data and CLIA certification of its internal lab. Yet reactions were mixed: a data preview on Jan 6, 2026 coincided with a +31.44% move, while detailed positive data on Jan 8, 2026 saw a -34.58% reaction. Today’s TD Cowen conference participation fits into a cadence of ongoing visibility events following these clinical milestones.
Key Terms
phosphoproteomics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Monday, March 2, 2026, at 1:50 p.m. ET at the TD Cowen 46th Annual Health Care Conference in Boston.
The live and archived webcast of this event can be accessed through a link on the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations.
About Acrivon Therapeutics
Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.
Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment.
In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company’s second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1 trial of ACR-2316 is advancing, with weekly dosing regimens established. Initial data has shown a favorable tolerability profile limited to transient, mechanism-based hematological adverse events, predominantly neutropenia and initial clinical activity across AP3-selected solid tumor types, including PRs in endometrial cancer, as well as SCLC and sqNSCLC, two tumor types which have not shown sensitivity to other clinical WEE1 or PKMYT1 inhibitors currently in development. In addition, the company is advancing ACR-6840, an internally discovered development candidate targeting CDK11.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.
Investor and Media Contacts:
Adam D. Levy, Ph.D., M.B.A.
alevy@acrivon.com
Alexandra Santos
asantos@wheelhouselsa.com
